December 27, 2023 10:34 AM ESTUpdated December 29, 10:11 AM
News Briefing

The­seus goes with Tang; Onc­ter­nal tri­al pa­tient dies; Lian­Bio sells drug rights to J&J

ENDPOINTS

Plus, news on the Im­munome-Atre­ca as­set deal, Cy­clo Ther­a­peu­tics’ re­verse merg­er, Nestlé buy­ing CDX-7108 from Codex­is, Onc­ter­nal, Vi­siox and more.

So long, Ap­plied Mol­e­c­u­lar …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times